Breakthrough in Acute Myeloid Leukemia Treatment: New Research Offers Hope for Refractory Patients

Strategic Insights -

Researchers at the University of Perugia have made significant strides in the treatment of Acute Myeloid Leukemia (AML), a type of blood cancer that is aggressive and often resistant to treatment. The study, published in the Annals of Hematology, focuses on the use of venetoclax/azacitidine (ven/aza) as a bridge-to-transplant therapy for AML patients who are refractory to intensive chemotherapy. According to the research, this treatment approach has shown extraordinary sensitivity in patients with IDH2 mutations, offering a promising alternative to intensive salvage chemotherapy.

Key Takeaways:

  • The use of venetoclax/azacitidine (ven/aza) in young and fit adults with AML remains limited, sparking ongoing debate about its potential role beyond patients ineligible for intensive chemotherapy.
  • The researchers presented three case reports of under 60-year-old AML patients with IDH2 mutations who were successfully treated with ven/aza as a bridge-to-transplant therapy.
  • These cases demonstrate the extraordinary sensitivity of IDH2-mutated AML to aza/ven even in the refractoriness setting.
  • This treatment approach has the potential to preserve patient fitness for allogenic transplantation.
  • The researchers emphasize the need for further studies to confirm these findings and explore the broader application of ven/aza in AML treatment.

Statistics:

  • The study was conducted at the University of Perugia in Perugia, Italy.
  • The three case reports presented in the study involved patients under 60 years old.
  • The treatment approach using venetoclax/azacitidine (ven/aza) resulted in successful outcomes for all three patients.
  • The researchers reported that the sensitivity of IDH2-mutated AML to aza/ven is "extraordinary" in the refractory setting.

Sources:

  • NewsRx. University of Perugia Reports Findings in Acute Myeloid Leukemia [Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept ...]. Chemicals & Chemistry. July 25, 2025; p 4417.
  • University of Perugia, Hematology and Clinical Immunology section, Center for Hemato-Oncology Research, Dept. of Medicine and Surgery, Perugia, Italy.
  • Springer, One New York Plaza, Suite 4600, New York, Ny, United States.